Revolution Medicines, Inc. (RVMDW) — SEC Filings
Revolution Medicines, Inc. (RVMDW) — 31 SEC filings. Latest: 10-Q (Nov 5, 2025). Includes 12 8-K, 9 SC 13G/A, 6 10-Q.
View Revolution Medicines, Inc. on SEC EDGAR
Overview
Revolution Medicines, Inc. (RVMDW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Revolution Medicines, Inc. (RVMDW) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $766.4 million, a substantial rise from $405.5 million in the same period of 2024. This expanded loss was primarily driven by a sharp increase in research and develop
Sentiment Summary
Across 31 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 28 neutral. The dominant filing sentiment for Revolution Medicines, Inc. is neutral.
Filing Type Overview
Revolution Medicines, Inc. (RVMDW) has filed 6 10-Q, 12 8-K, 2 DEF 14A, 2 10-K, 9 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (31)
Risk Profile
Risk Assessment: Of RVMDW's 23 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$766.4M |
| EPS | -$1.61 |
| Cash Position | $217.4M |
| Total Assets | $2.25B |
| Total Debt | $655.0M |
Key Executives
- Jeff Cislini
Industry Context
Revolution Medicines operates in the highly competitive and innovation-driven oncology drug development sector. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies like Revolution Medicines focus on developing novel targeted therapies, often requiring substantial capital investment to advance through clinical trials and secure regulatory approvals.
Top Tags
Biotechnology (4) · 8-K (4) · 10-Q (4) · biotech (4) · institutional-ownership (4) · amendment (4) · Revolution Medicines (3) · Net Loss (2) · Cash Burn (2) · regulatory-filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $766.4M | Increased from $405.5M in 2024, indicating widening losses. |
| Research and Development Expenses | $692.4M | Up 71.3% from $404.1M in 2024, driving increased operating costs. |
| Cash and Cash Equivalents | $217.4M | Decreased from $543.1M at Dec 31, 2024, reflecting significant cash burn. |
| Accumulated Deficit | $2.5B | As of September 30, 2025, highlighting historical losses. |
| Liability from Sale of Future Royalties | $256.5M | New liability impacting total liabilities, which more than doubled. |
| Common Shares Outstanding | 189,710,951 | As of September 30, 2025, up from 185,896,625 at Dec 31, 2024. |
| Net Loss Per Share (Q3 2025) | $1.61 | Increased from $0.94 in Q3 2024, reflecting higher losses per share. |
| Total Cash, Cash Equivalents and Marketable Securities | $1.93B | Management believes this will fund operations for at least 12 months. |
| Cash & Equivalents | $500.0M | Decreased by $100.0M from $600.0M at year-end 2024, showing significant cash burn. |
| Increase in Net Loss | 25% | Calculated as ($150.0M - $120.0M) / $120.0M, highlighting accelerated losses. |
| Decrease in Cash | 16.7% | Calculated as ($600.0M - $500.0M) / $600.0M, indicating cash depletion. |
| Reporting Period End | 2025-06-30 | Latest financial snapshot for the company's performance. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the fiscal quarter for which the report is filed. |
| Previous Year End Date | 2024-12-31 | Provides a comparative point for financial analysis. |
| Prior Year End Date | 2023-12-31 | Offers further historical context for financial trends. |
Forward-Looking Statements
- {"claim":"The Column Group III, LP will maintain its passive investment strategy in Revolution Medicines, Inc.","entity":"The Column Group III, LP","targetDate":"Next 12 months","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Revolution Medicines, Inc. (RVMDW)?
Revolution Medicines, Inc. has 31 recent SEC filings from Jan 2024 to Nov 2025, including 12 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RVMDW filings?
Across 31 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 28 neutral. The dominant sentiment is neutral.
Where can I find Revolution Medicines, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Revolution Medicines, Inc. (RVMDW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Revolution Medicines, Inc.?
Key financial highlights from Revolution Medicines, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RVMDW?
The investment thesis for RVMDW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Revolution Medicines, Inc.?
Key executives identified across Revolution Medicines, Inc.'s filings include Jeff Cislini.
What are the main risk factors for Revolution Medicines, Inc. stock?
Of RVMDW's 23 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Revolution Medicines, Inc.?
Recent forward-looking statements from Revolution Medicines, Inc. include guidance on {"claim":"The Column Group III, LP will maintain its passive investment strategy in Revolution Medicines, Inc.","entity".